Trusted Resource for Clinical Trials, Protocols & Progress
Bioanalytical method validation is the cornerstone of generating reliable, reproducible, and regulatory-compliant data in clinical studies. Whether for pharmacokinetic (PK), toxicokinetic (TK), or biomarker analyses, the analytical method must demonstrate validated performance throughout the sample testing lifecycle.
Click to read the full article.
In clinical trials, the bioanalytical reliability of plasma, serum, urine, cerebrospinal fluid (CSF), and tissue samples depends heavily on storage integrity. Regulatory agencies expect sponsors and labs to define and validate storage conditions that are specific to the biological matrix type being analyzed. Failure to meet these expectations can result in data rejection, regulatory observations, or CAPA requirements.
Click to read the full article.
Stability of analytes in clinical trial samples is critical for producing scientifically reliable and regulatory-compliant data. Analyte degradation due to temperature fluctuations, prolonged exposure, or excessive freeze-thaw cycles can lead to variability in pharmacokinetic (PK) or biomarker data. This not only jeopardizes study outcomes but can also attract regulatory observations during inspections.
Click to read the full article.
Bioanalytical testing forms the backbone of clinical pharmacology data in every clinical trial. From pharmacokinetics (PK) to biomarker and immunogenicity testing, the reliability of data hinges on the performance, systems, and compliance culture of the bioanalytical laboratory. Regulatory agencies such as the FDA and EMA require sponsors to demonstrate oversight of outsourced bioanalysis, whether conducted in-house or through a third-party contract research organization (CRO).
Click to read the full article.
In large-scale clinical trials, efficient sample management is essential to minimize waste, improve throughput, and ensure timely analysis. Sample pooling and aliquoting are two widely used practices in bioanalytical laboratories for optimizing resources. However, both processes come with regulatory risks, particularly when poorly documented or improperly executed.
Click to read the full article.
In the clinical development lifecycle, proper storage of biological samples is a foundational component for ensuring data reliability and compliance. Whether intended for pharmacokinetic (PK) analysis, biomarker evaluation, or future reanalysis, these samples must be handled under strict quality control (QC) protocols to maintain their stability and traceability over time.
Click to read the full article.
As clinical trial sponsors increasingly outsource bioanalytical activities to contract research organizations (CROs) or third-party laboratories, regulatory expectations around oversight and compliance have intensified. While outsourcing offers scalability, specialized expertise, and cost efficiency, it also introduces complex risks related to data integrity, regulatory alignment, and subject safety.
Click to read the full article.
Bioanalytical testing plays a vital role in determining the safety and efficacy of investigational products in clinical trials. Given its pivotal position, regulatory agencies require bioanalytical procedures to meet either Good Laboratory Practice (GLP), Good Clinical Practice (GCP), or both, depending on the stage and scope of the trial. While GLP governs non-clinical safety data and is typically used for preclinical toxicology studies, GCP applies to studies involving human subjects and governs clinical trial conduct.
Click to read the full article.
Data reconciliation between clinical sites and bioanalytical laboratories is a critical step in ensuring the accuracy, completeness, and traceability of clinical trial data. Mismatches between what is documented at the site (e.g., sample collection times, subject identifiers, protocol deviations) and what is recorded in laboratory systems (e.g., LIMS, chromatography outputs, stability logs) can lead to serious regulatory non-compliance and threaten trial validity.
Click to read the full article.
In recent years, biomarkers have become integral to clinical development, serving critical roles in patient stratification, endpoint analysis, and therapeutic monitoring. However, due to their often unstable nature, proper storage of biomarker samples has emerged as a major focus area for global regulatory authorities.
Click to read the full article.
